BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 1997853)

  • 21. Late cardiotoxicity after treatment for a malignant bone tumor.
    Postma A; Bink-Boelkens MT; Beaufort-Krol GC; Kengen RA; Elzenga NJ; Schasfoort-van Leeuwen MJ; Schraffordt koops H; Kamps WA
    Med Pediatr Oncol; 1996 Apr; 26(4):230-7. PubMed ID: 8600333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The erythrocyte sedimentation rate in congestive heart failure.
    Haber HL; Leavy JA; Kessler PD; Kukin ML; Gottlieb SS; Packer M
    N Engl J Med; 1991 Feb; 324(6):353-8. PubMed ID: 1987458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
    Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
    Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.
    Lipshultz SE; Lipsitz SR; Sallan SE; Simbre VC; Shaikh SL; Mone SM; Gelber RD; Colan SD
    J Clin Oncol; 2002 Dec; 20(23):4517-22. PubMed ID: 12454107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
    Speyer JL; Green MD; Kramer E; Rey M; Sanger J; Ward C; Dubin N; Ferrans V; Stecy P; Zeleniuch-Jacquotte A
    N Engl J Med; 1988 Sep; 319(12):745-52. PubMed ID: 3137469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
    Lipshultz SE; Giantris AL; Lipsitz SR; Kimball Dalton V; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE; Colan SD
    J Clin Oncol; 2002 Mar; 20(6):1677-82. PubMed ID: 11896119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.
    Nysom K; Holm K; Lipsitz SR; Mone SM; Colan SD; Orav EJ; Sallan SE; Olsen JH; Hertz H; Jacobsen JR; Lipshultz SE
    J Clin Oncol; 1998 Feb; 16(2):545-50. PubMed ID: 9469339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of echocardiography versus cardiac troponin I levels in the early detection of anthracycline cardiotoxicity in childhood acute leukemia: prospective evaluation of a 7-year-long clinical follow-up.
    Oztarhan K; Guler S; Aktas B; Arslan M; Salcioglu Z; Aydogan G
    Pediatr Hematol Oncol; 2011 Aug; 28(5):380-94. PubMed ID: 21699467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac function in Wilms' tumor survivors.
    Sorensen K; Levitt G; Sebag-Montefiore D; Bull C; Sullivan I
    J Clin Oncol; 1995 Jul; 13(7):1546-56. PubMed ID: 7602343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility.
    Colan SD; Parness IA; Spevak PJ; Sanders SP
    J Am Coll Cardiol; 1992 Mar; 19(3):619-29. PubMed ID: 1538019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
    Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
    J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Afterload reduction and vasodilator therapy (author's transl)].
    Sasayama S
    Nihon Yakurigaku Zasshi; 1981 Sep; 78(3):127-37. PubMed ID: 7035310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
    Schwartz RG; McKenzie WB; Alexander J; Sager P; D'Souza A; Manatunga A; Schwartz PE; Berger HJ; Setaro J; Surkin L
    Am J Med; 1987 Jun; 82(6):1109-18. PubMed ID: 3605130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.
    Rammeloo LA; Postma A; Sobotka-Plojhar MA; Bink-Boelkens MT; Berg A; Veerman AJ; Kamps WA
    Med Pediatr Oncol; 2000 Jul; 35(1):13-9. PubMed ID: 10881002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
    Alexander J; Dainiak N; Berger HJ; Goldman L; Johnstone D; Reduto L; Duffy T; Schwartz P; Gottschalk A; Zaret BL
    N Engl J Med; 1979 Feb; 300(6):278-83. PubMed ID: 759880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children.
    Goorin AM; Borow KM; Goldman A; Williams RG; Henderson IC; Sallan SE; Cohen H; Jaffe N
    Cancer; 1981 Jun; 47(12):2810-6. PubMed ID: 6942908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myocardial function and postmortem myocardial histology in children given anthracycline therapy for cancer.
    Pihkala J; Sariola H; Saarinen UM
    Pediatr Hematol Oncol; 1994; 11(3):259-69. PubMed ID: 8060810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.
    Lipshultz SE; Lipsitz SR; Kutok JL; Miller TL; Colan SD; Neuberg DS; Stevenson KE; Fleming MD; Sallan SE; Franco VI; Henkel JM; Asselin BL; Athale UH; Clavell LA; Michon B; Laverdiere C; Larsen E; Kelly KM; Silverman LB
    Cancer; 2013 Oct; 119(19):3555-62. PubMed ID: 23861158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling.
    Hausdorf G; Morf G; Beron G; Erttmann R; Winkler K; Landbeck G; Keck EW
    Br Heart J; 1988 Oct; 60(4):309-15. PubMed ID: 3190959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia.
    Hagag AA; El Shehaby WA; El-Abasy AI; Mabrouk MM
    Infect Disord Drug Targets; 2019; 19(2):133-140. PubMed ID: 30073931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.